Jeremy P. Springhorn
CIK 1717852 · Chief Business Officer · last filed 2026-06-12
Jeremy P. Springhorn is a Chief Business Officer who has filed 25 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for QURE, was dated Jun 12, 2026. Across all open-market trades the lifetime net is −$28.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
QURE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1 HARTWELL PLACE
LEXINGTON, MA
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QURE | Director | 43,251 | $24.93 | $1.08M | -$263.9K | 18 | 2026-06-12 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Chief Business Officer | 2,488 | $0.00 | $1 | $235.9K | 6 | 2021-02-19 |
Recent Filings
25 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | QURE | Mixed | +5,557 | -$53.9K | EDGAR |
| 2026-06-11 | QURE | Notice (144) | −1,993 | -$53.9K | EDGAR |
| 2025-06-24 | QURE | Sell (S) | −2,112 | -$30.5K | EDGAR |
| 2025-06-13 | QURE | Grant (A) | +7,970 | $0 | EDGAR |
| 2024-06-21 | QURE | Grant (A) | +8,080 | $0 | EDGAR |
| 2024-06-17 | QURE | Sell (S) | −2,231 | -$11.4K | EDGAR |
| 2023-06-20 | QURE | Mixed | +6,414 | -$43.2K | EDGAR |
| 2023-03-01 | QURE | Sell (S) | −384 | -$7.8K | EDGAR |
| 2022-06-17 | QURE | Grant (A) | +9,080 | $0 | EDGAR |
| 2022-03-02 | QURE | Sell (S) | −602 | -$10.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.